HK Stock Market Move | HENLIUS (02696) is now up over 3%. The company has obtained an EU GMP certificate and recently signed a license agreement with FBD.

HENLIUS (02696) is now up more than 3%, at the time of writing, up 3.25% to HK$54, with a trading volume of HK$169.082 million. In terms of news, HENLIUS announced that its wholly-owned subsidiary Hanlin Pharma has received two GMP certificates from the Belgian Federal Agency for Medicines and Health Products. The GMP certification covers production facilities including the HLX11 raw material production line, formulation production line, and packaging production line, as well as the HLX14 raw material production line, formulation line 2, formulation line 3, and packaging production line. After obtaining the GMP certificate, HLX11 and HLX14 still need to obtain EU Marketing Authorization Application (MAA) approval before they can be marketed in the EU. Additionally, HENLIUS recently announced that it has signed a License Agreement with FBD, under which the two parties will collaborate on the development, production, and commercialization of FBD's SIRP-Fc fusion protein (HCB101) and drugs containing this molecule as the active ingredient in the agreed upon licensing region and field. HENLIUS will pay FBD up to $59 million and up to $143 million in commercial milestones based on annual net sales of the licensed product in region 1.